Semaglutide Shows Kidney and Survival Benefits for Diabetes and Kidney Disease Patients

A recent analysis of the FLOW trial indicates that semaglutide offers significant improvements in kidney function and overall survival for individuals with type 2 diabetes and chronic kidney disease. These positive effects were observed across diverse patient groups, including those with existing cardiovascular conditions. The findings highlight the drug's potential to reduce serious health risks in this vulnerable population.